Russia’s public health watchdog Rospotrebnadzor affirmed on Tuesday that the EpiVacCorona COVID-19 vaccine, the second jab that Moscow recorded, has proved a 100% efficacy in the clinical trials.
The evaluation was based on the data collected during the first two phases of the jab’s clinical trial, the statement read.
The vaccine, developed by the Vector Institute, was filed in October and entered the third phase of the trial a month later.
What's happening in Tunisia?
Subscribe to our Youtube channel for updates.
